Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

Sub-analysis of TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan featured as late-breaking Mini Oral presentation at ESMO TROPION-Lung05 phase 2 trial currently enrolling patients to further evaluate the safety and efficacy of datopotamab...

Full "IntellAsia: Resources" article